Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × tazemetostat × Clear all

Phase

Status

Completed 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 4 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, B-Cell 3 Sarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Multiple Myeloma 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Chordoma 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 15 Cytarabine 12 fludarabine 11 Azacitidine 11 Gemcitabine 9 pomalidomide 8 glofitamab 7 Rituximab 7 Lenalidomide 7 Carboplatin 7 selinexor 6 Temozolomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 daratumumab 5 Paclitaxel 5 Oxaliplatin 5 Nivolumab 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Immunotherapy, Adoptive 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06824701 2025-12-03

TARZAN

University of Utah

Phase 1 Recruiting

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡